Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 22 Jul 2024 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role: 10%+ Owner
Signature: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Jennifer C. Boylan, Title: Authorized Person
Issuer symbol: ARTV
Transactions as of: 22 Jul 2024
Net transactions value: +$499,994
Form type: 4
Filing time: 22 Jul 2024, 20:28:17 UTC
Previous filing: 18 Jul 2024
Next filing: 12 Sep 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARTV	Common Stock	Conversion of derivative security		+145,089			145,089	22 Jul 2024	Direct	F1
transaction	ARTV	Common Stock	Other	$499,994	+49,019	+34%	$10.20^*	194,108	22 Jul 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARTV	Series B Preferred Stock	Conversion of derivative security		-145,089	-100%		0	22 Jul 2024	Common Stock	145,089		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
F2	Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

Content

Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.

Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.